Mener Amanda, Patel Seema R, Arthur Connie M, Stowell Sean R
Center for Transfusion Medicine and Cellular Therapies, Department of Laboratory Medicine and Pathology, Emory University School of Medicine, Atlanta, Georgia.
Transfusion. 2019 Jan;59(1):371-384. doi: 10.1111/trf.14939. Epub 2018 Nov 26.
Anti-RhD administration can prevent de novo anti-RhD formation following RhD+ red blood cell (RBC) exposure, termed antibody-mediated immunosuppression (AMIS). Recent studies suggest that AMIS may occur through target antigen alterations, known as antigen modulation. However, studies suggest that AMIS may occur independent of antigen modulation. In particular, AMIS to RBCs that transgenically express the fusion hen egg lysozyme-ovalbumin-Duffy (HOD) antigen have been shown to occur independent of activating Fcγ receptors (FcγRs) thought to be required for antigen modulation. Therefore, we sought to determine the mechanism behind AMIS following HOD RBC exposure.
Following transfer of HOD RBCs into wild-type or FcγR-chain knockout recipients in the presence or absence of monoclonal anti-hen egg lysozyme (HEL) antibody, individually or in combination, HOD antigen levels and anti-HOD antibody formation were examined.
Our results demonstrate that anti-HEL antibodies individually or in combination suppressed anti-HOD IgM, which correlated with the rate of detectable decrease in HEL on HOD RBCs. Furthermore, exposure to anti-HEL antibodies alone or in combination equally suppressed anti-HOD IgG formation. Unexpectedly, combination or individual anti-HEL antibodies induced AMIS and antigen modulation in an FcγR-independent manner. Pre-exposure of HOD RBCs to anti-HEL antibodies reduced antigen levels and suppressed anti-HOD antibody formation following HOD RBC exposure.
These results suggest that antibody-mediated antigen modulation may reflect a mechanism of AMIS that can occur independent of activating FcγRs and may provide a surrogate to identify antibodies capable of inducing AMIS against different RBC antigens.
给予抗RhD药物可预防RhD阳性红细胞(RBC)暴露后产生新的抗RhD,这一过程称为抗体介导的免疫抑制(AMIS)。最近的研究表明,AMIS可能通过靶抗原改变(即抗原调制)而发生。然而,研究表明AMIS可能独立于抗原调制而发生。特别是,已证明对转基因表达融合型鸡卵溶菌酶-卵清蛋白-达菲(HOD)抗原的RBC产生的AMIS独立于被认为是抗原调制所必需的激活Fcγ受体(FcγR)而发生。因此,我们试图确定HOD RBC暴露后AMIS背后的机制。
在存在或不存在单克隆抗鸡卵溶菌酶(HEL)抗体的情况下,将HOD RBC单独或联合转移到野生型或FcγR链敲除受体中,检测HOD抗原水平和抗HOD抗体的形成。
我们的结果表明,单独或联合使用抗HEL抗体可抑制抗HOD IgM,这与HOD RBC上HEL可检测到的下降速率相关。此外,单独或联合暴露于抗HEL抗体同样可抑制抗HOD IgG的形成。出乎意料的是,联合或单独使用抗HEL抗体以FcγR非依赖性方式诱导AMIS和抗原调制。HOD RBC预先暴露于抗HEL抗体可降低抗原水平,并抑制HOD RBC暴露后抗HOD抗体的形成。
这些结果表明,抗体介导的抗原调制可能反映了一种AMIS机制,其可独立于激活FcγR而发生,并可能提供一种替代方法来鉴定能够诱导针对不同RBC抗原的AMIS的抗体。